Across TCGA pan-cancer cohorts, FHIT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FHIT data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FHIT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FHIT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where FHIT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.885	.002	61	view →
HNSC	DFS	Median	II,III,IV	0.897	0.993	.005	15	view →
LUAD	DFS	Quartile	III,IV	0.335	0.967	<.001	9	view →
PDAC	OS	Quartile	All	1.000	0.584	.001	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FHIT tumor-vs-normal RNA expression · all FHIT data types